|
Vyome Biosciences Completes Enrollmentfor Proof of Concept Clinical Study of VB-1953
Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes today announced it completed enrollment in its proof-of-concept study ofVB1953...
|
|
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
BD , a leading global medical technology company announced the global distribution of a complete portfolio of products for mass spectrometry that provides high-speed and high-confidence identification of pathogens in clinical laboratories...
|
|